News Sentiment

CAI sentiment intelligence

Caris Life Sciences, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 78 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 16.49 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 70

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-2.9% over one week, -10.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Caris Life Sciences, Inc. - Common Stock (CAI) Stock Price, News, Quote & History

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -2.9% Price reacting lower
Trend fit Trend inactive -10.7% over four weeks
Fair value -33.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 47
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 70
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 12
simplywall.st 6
PR Newswire 5
MarketBeat 3
Morningstar 3
The Globe and Mail 2
TIKR.com 2

Event Lens

What the news is about

Classified themes
Market update 44
Earnings 22
Analyst action 5
Capital return 3
Balance sheet 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 78
Stock Titan Direct company coverage

Director takes Caris Life Sciences (CAI) 2026 board fees in stock

Caris Life Sciences director Jonathan Kenneth Charles Knowles received 1,600 shares of common stock on May 29, 2026, as compensation for his 2026 board retainer fees. These shares were granted in lieu of cash, based on a ten-day volume weighted average price calculation of $15.62

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jun 2026 22:40
Source
Stock Titan
BioSpace Direct company coverage

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences has launched its "Behind the Diagnosis" campaign to highlight how its comprehensive genomic testing and AI-powered precision medicine have transformed patient care. The inaugural story features Erika Rios, whose initial diagnosis of stage 4 metastatic breast c

Tone
Positive 74/100
Event
Market update
Published
01 Jun 2026 22:09
Source
BioSpace
Stock Titan Direct company coverage

Caris Life (CAI) director granted 1,600 shares for 2026 board fees

Caris Life Sciences director George Poste received 1,600 shares of common stock as compensation for his 2026 board retainer fees, granted at a reference price of $15.62 per share. This equity award, given in lieu of cash, brings his direct holdings to 17,729 shares. Additionally,

Tone
Neutral 50/100
Event
Balance sheet
Published
31 May 2026 17:39
Source
Stock Titan
Finviz Direct company coverage

CAI - Caris Life Sciences Inc Stock Price and Quote

This article provides a detailed stock quote and financial data for Caris Life Sciences Inc. (CAI), including its latest closing price, market capitalization, key financial ratios, and analyst ratings. It also lists recent news announcements and insider trading activities related

Tone
Positive 65/100
Event
Analyst action
Published
30 May 2026 09:39
Source
Finviz
Morningstar Direct company coverage

Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence

Caris Life Sciences, along with the Caris Precision Oncology Alliance and over 60 collaborators, will present 32 studies at the 2026 ASCO Annual Meeting. These studies focus on multi-omic biomarker research and real-world data to enhance understanding of tumor biology and guide p

Tone
Positive 73/100
Event
Market update
Published
20 May 2026 05:09
Source
Morningstar
Stock Titan Direct company coverage

Caris Life Sciences (CAI) exec has 6,047 shares withheld for RSU taxes

Caris Life Sciences executive John Russel Denton had 6,047 shares of common stock withheld at $15.25 per share to cover RSU taxes on May 15, 2026. This transaction is categorized as a non-market tax-withholding disposition, not an open-market sale. Following this activity, Denton

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:40
Source
Stock Titan
Stock Titan Direct company coverage

Caris Life Sciences (CAI) logs RSU tax share withholding

Caris Life Sciences president David Baxley Spetzler reported a routine tax-withholding disposition for 13,856 shares of common stock at $15.25 per share, covering taxes related to vested Restricted Stock Units (RSUs). Following this transaction, Spetzler directly owns 530,083 sha

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:40
Source
Stock Titan
Stock Titan Direct company coverage

Caris Life Sciences (CAI) director logs RSU tax withholding and large indirect stake

Caris Life Sciences director David D. Halbert reported a routine disposition of 40,712 shares of Common Stock to cover tax obligations related to the vesting of restricted stock units (RSUs) at a price of $15.25 per share. After this transaction, Mr. Halbert directly holds 2,574,

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 May 2026 04:40
Source
Stock Titan
MarketBeat Direct company coverage

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences is expanding its precision oncology platform, product pipeline, and biopharma partnerships after its IPO last June, seeing significant growth potential in the oncology market, which is currently only about 35% penetrated. The company reported a 79% year-over-y

Tone
Positive 94/100
Event
Earnings
Published
17 May 2026 20:10
Source
MarketBeat
Intellectia AI Direct company coverage

Druckenmiller's Duquesne Office Invests in Broadcom and Caris Life Sciences

Duquesne Family Office, led by Stanley Druckenmiller, made significant investment shifts in Q1 2026, acquiring shares in Broadcom (AVGO) and Caris Life Sciences (CAI) while exiting positions in Alphabet Class A and Cogent Biosciences. The firm also increased its holdings in STMic

Tone
Positive 66/100
Event
Market update
Published
15 May 2026 21:09
Source
Intellectia AI
The Globe and Mail Direct company coverage

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)

Two healthcare stocks, Crispr Therapeutics AG (CRSP) and Caris Life Sciences, Inc. (CAI), have received bullish sentiments from analysts. Crispr Therapeutics AG was maintained with a Buy rating and an $83 price target by Bank of America Securities, with a Moderate Buy consensus a

Tone
Neutral 50/100
Event
Analyst action
Published
15 May 2026 08:08
Source
The Globe and Mail
Stock Titan Direct company coverage

[SCHEDULE 13G/A] Caris Life Sciences, Inc. Amended Passive Investment Disclosure

TSSP Sub-Fund HoldCo, LLC and Alan Waxman have jointly filed an amended Schedule 13G/A, disclosing their beneficial ownership stakes in CARIS Life Sciences, Inc. As of March 31, 2026, TSSP Sub-Fund HoldCo holds 4.8% of outstanding common stock, while Alan Waxman holds 5.1%, both

Tone
Neutral 50/100
Event
Market update
Published
12 May 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

J.H. Whitney reports 18.26M shares of Caris Life Sciences (CAI)

J.H. Whitney VI, L.P. and its affiliated reporting persons have disclosed a beneficial ownership of 18,256,615 shares of Caris Life Sciences, Inc. (CAI) common stock, which represents 6.5% of the class. This information was reported in an amended Schedule 13G filing. The reportin

Tone
Neutral 50/100
Event
Market update
Published
12 May 2026 14:39
Source
Stock Titan
Stock Titan Direct company coverage

Director buys 31K Caris Life Sciences (CAI) shares around $16.15

Caris Life Sciences director Jeff L. Vacirca purchased 31,050 shares of Common Stock in an open-market transaction at a weighted average price of $16.149 per share. This purchase increased his direct ownership to 49,671 shares. The transaction is viewed positively and was reporte

Tone
Positive 77/100
Event
Market update
Published
12 May 2026 12:32
Source
Stock Titan
Stock Titan Direct company coverage

Surging revenue lifts Caris Life Sciences (CAI) toward profit in Q1 2026

Caris Life Sciences (CAI) reported strong Q1 2026 growth, with total revenue nearly doubling to $216.174 million, primarily driven by molecular profiling services. The company achieved income from operations of $5.282 million and narrowed its net loss to $0.510 million, indicatin

Tone
Positive 67/100
Event
Earnings
Published
08 May 2026 20:09
Source
Stock Titan
Morningstar Direct company coverage

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization

Caris Life Sciences has submitted an application to the New York State Department of Health (NYSDOH) for authorization of its Caris Assure blood-based molecular profiling test. This test, which analyzes whole exome and transcriptome, is designed to support comprehensive biomarker

Tone
Positive 67/100
Event
Market update
Published
08 May 2026 20:05
Source
Morningstar